Osiris Therapeutics Inc. (OSIR)

[3ch0]

Starting to settle.

[3ch0]

Premarket hits coming threw.

[3ch0]

Looking good

[3ch0]

Hmmm

[Tradescott818]

Nope
Going to ZERO!

[Little Trader ATWOOD]

I agree, best of luck to you my friend

[3ch0]

Exactly !! I see a reversal coming very shortly imo. Very undervalued of late.

[Little Trader ATWOOD]

One for 59,000 shares and 1 for 31,000 90,000 * 5.2= 468,000 I'm expecting big news from the presentation!!!

[3ch0]

The other one is ridiculous,wow.

[3ch0]

Yeah it was, upwards of 160k alone.

[Little Trader ATWOOD]

Huge trades after hours

[3ch0]

Good support , strong close

[3ch0]

Looking into Osiris, interesting company and circumstances.

[vectorinformatics]

Steinmeyer Law launches investigation into OSIR Steinmeyer Law launches investigation into OSIR

[hbhmb]

this board is about osir not another stock


please stop hyping on the wrong board.

[Canoepaddler]

Just took a position in $OSIR.

[expediter13]

I still wonder about that because their sales keep going up. Problem with this company is their PR's. Obviously, they have to cover the blunder from last year.Also the output on their cells they sold off to Mesoblast. Once Meso's trial fails, they will be looking to blame someone..

Osiris put a spin on that PR and meso bought it, cheap, would you sell a multibillion dollar product for 20M... NO! Then why would these guys, and why would meso buy it... ?

Answer ; O knew it would go nowhere... and Meso needed something to sustain their run above water.... bottom line, meso, athx, neostem, all of them are junk companies working on stock capital...

Osiris on the other hand may have a homerun, PR mistakes aside... The grafix strips are working, and most importantly, selling...

[RealGenius]

Napadano sees big downside in Medicare reimbursement rates for OSIR.

[alldat070]

Osiris Therapeutics: Poised For Another Breakout

http://seekingalpha.com/article/2079783-osiris-therapeutics-poised-for-another-breakout?source=etrade

[alldat070]

so if shorts want to get out the sell on short squeeze which makes the pps rise. I am asking why the pps is dropping?

[MikeBK205]

Shorts mean people who make a huge profit and sell quickly!!! They aren't in for a long term investment ... Longs are those who wait patiently or keep accumulating as pps goes up over time....

[alldat070]

whats that mean the shorts want out because its going to go up?

[MikeBK205]

Because of shorts!!!!

[alldat070]

Whats your though on this. Got in before the earnings news but don't get why the drop with such promising news?

[alldat070]

Huge Earnings News. This is going to be one to hold

[surf1944]

8:33AM Osiris Therapeutics announces receipt of $15 mln milestone payment for Prochymal (OSIR) : Co announces that it has received a $15 mln milestone payment from Mesoblast for successful completion of the transfer of assets relating to the Prochymal business. In Oct 2013, OSIR announced an agreement with a wholly-owned subsidiary of Mesoblast Limited for the acquisition of OSIRs' culture-expanded mesenchymal stem cell business, including Prochymal, in a transaction worth up to $100 mln in initial consideration and milestone payments as well as future royalties. The milestone that was achieved was in consideration of transition and delivery of the major assets related to its ceMSC business. The payment was made in Mesoblast equity with customary downside protection after the 12-month holding period. OSIR continues to provide services to Mesoblast as part of the agreement to ensure a smooth transition. As a result of the transaction, OSIR expects to report a profit for the fourth quarter 2013 and full fiscal year.

[surf1944]

8:37AM Osiris Therapeutics announces Journal Published Grafix clinical study for Chronic wounds; Grafix demonstrates an overall closure rate of 76% among chronic wounds further supporting evidence from its recent diabetic foot ulcer trial (OSIR) 14.96 : Co announces that that data, published in Ostomy Wound Management, shows that the use of Grafix on a variety of chronic wounds resulted in an overall closure rate of 76% by 12 weeks, including 68% of Venous Leg Ulcers and 85% of Diabetic Foot Ulcers treated. The publication is available in the December 2013 issue of Ostomy Wound Management and on its website.

The study evaluated the use of Grafix in 67 chronic wounds (66 patients), including 34 VLUs, 27 DFUs, and 6 other chronic wounds. Patients evaluated in this study had a mean wound duration prior to treatment of 38 weeks indicating the truly refractory nature of these wounds. Additionally, 75% of the patients in this study had failed at least one advanced wound therapy prior to receiving Grafix. Among the patients that closed, the mean time to closure was 5.8 weeks with an average of 3.2 applications. Additionally, no Grafix-related adverse events were reported and no wound recurrences were observed among patients that closed with a mean follow-up of 20.4 months.

Commentary: "This data is a nice compliment to our multi-center, randomized, controlled trial in DFUs, which showed that Grafix had overwhelming efficacy with a relative effect of 191% when compared to control treatment. We are pleased to offer patients, including those with limited treatment options, a novel, cellular treatment with conclusive clinical evidence. More importantly, healing wounds quickly with fewer treatments is cost-effective, and better for patients, physicians, and payors."

[ADVFN_aligato]

"Motley Fool article
Today, from Motley Fool:

"Osiris sold Prochymal for what amounts to $100 million in upfront and royalty payments, and this move eliminates a major cost that was weighing heavily on the bottom line. The liquidation of Prochymal combined with increasing sales of Osiris' wound healing... More
Sentiment: Strong Buy"

[shanak10]

What a bloody day here today. I am relatively new to reading 8K's and am not sure what triggered today's action.

[surf1944]

9:04AM Osiris Therapeutics and FDA reach agreement on regulatory pathway for Biosurgery Products (OSIR) 17.48 : OSIR announced that it has reached agreement with the United States Food and Drug Administration (FDA) regarding the regulatory pathway for its Biosurgery products, Grafix and Ovation.

After discussions with the FDA, the regulatory status of Grafix is confirmed and the product will remain on the market as a wound cover for the treatment of acute and chronic wounds. For certain expanded indications for Grafix, Osiris has committed to submit a Biologics License Application (BLA).
Osiris will leverage existing clinical data in the preparation of the applications, including data from Protocol 302, its multi-center, randomized controlled trial which demonstrated a 192% relative improvement in closure rate of chronic diabetic foot ulcers as compared to patients receiving conventional therapy (p<0.0001).
Additionally, Osiris will continue transitioning its Ovation product line over to the company's newly launched OvationOS formulation and has agreed to complete this transition no later than the second half of 2014.

[surf1944]

1:59AM Osiris Therapeutics announces agreement for culture-expanded MSCs including Prochymal worth up to $100 mln plus royalties (OSIR) 17.13 : Osiris Therapeutics (OSIR), announces that it has entered into an agreement with a wholly-owned subsidiary of Mesoblast for the sale of Osiris' culture-expanded mesenchymal stem cell business, including Prochymal, in a transaction worth up to $100 mln in initial consideration and milestone payments. Additionally, Osiris will receive royalty payments on sales of Prochymal and other products utilizing the acquired ceMSC technology.

Summary of the Transaction


Mesoblast has acquired the assets related to Osiris' ceMSC business.
Osiris will receive $50 mln in consideration for closing and delivery of its ceMSC assets.
Osiris is eligible to receive up to an additional $50 mln in payments upon Mesoblast achieving certain clinical and regulatory milestones.
Mesoblast will assume all future development costs for the ceMSC business.
Osiris will receive single to low double-digit royalties on product sales derived from the ceMSC technology.
Osiris and Mesoblast have entered into a separate services agreement for continued product advancement and to ensure a seamless transition.
Osiris has retained a license to all transferred intellectual property necessary to run its other businesses.
For Osiris, the transaction results in pro forma cash, investments and receivables of ~$82 mln.

[surf1944]

Grafix® Featured in Multiple Abstracts at the 2013 Fall Symposium on Advanced Wound Care
Business WirePress Release: Osiris Therapeutics, Inc. – Thu, Sep 26, 2013 10:00 AM EDT

COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris Therapeutics, Inc. (OSIR), announced today that data from seven studies will be presented at the 2013 Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas. The information presented will range from basic mechanistic science through human clinical trials.
The healing potential of Grafix® will be described in three of the abstracts by comparing the angiogenic, anti-inflammatory, and antioxidant effects of the cellular repair matrix to those of acellular human repair matrices (LB-136, LB-137 and LB-138). Additionally, four studies detailing the results of Grafix in various clinical settings will be presented, including the treatment of diabetic foot ulcers, venous leg ulcers and chronic wounds in patients undergoing long-term treatment with corticosteroids (CS-054, CS-060, CS-061 and Session 1 – Presentation).
“Osiris has been conducting cutting edge research in cell therapy for more than 20 years, providing us with scientific insight that no other company in the space can match,” said Michelle LeRoux Williams, Ph.D., Chief Scientific Officer. “Our deep understanding of the science enables us to offer our physicians and patients the highest quality products, tested to the most rigorous standards and designed to achieve the best possible outcomes.”
The conference will feature a podium presentation by Dr. Larry Lavery, Principal Investigator for the recent Grafix trial and Professor of Plastic Surgery at the University of Texas Southwestern Medical Center. Dr. Lavery will discuss the primary and secondary endpoints and key safety data from Protocol 302, a multi-center, randomized, controlled clinical trial evaluating Grafix for the treatment of diabetic foot ulcers.
The 26th Symposium on Advanced Wound Care Fall Conference is held from September 27th to 29th. The meeting is the largest wound care conference in the country and is the official conference of the Association for the Advancement of Wound Care (AAWC). Visit Osiris at SAWC Booth 422.
About the Trial (Protocol 302)
Protocol 302 is a single-blind, randomized, controlled multi-center trial evaluating the efficacy and safety of weekly applications of Grafix for the treatment of chronic diabetic foot ulcers. A total of 131 patients were enrolled at 19 leading wound care centers across the United States. Patients between 18 and 80 years of age with confirmed type 1 or type 2 diabetes and chronic diabetic foot ulcers on the dorsal or plantar surface of the foot were randomized to Grafix or control dressings at a 1:1 ratio. Ulcers had to be present for at least 4 weeks prior to randomization and between 1 cm2 and 15 cm2 in size. Patients were excluded from the trial if the ulcer decreased with more than 30% during the one week screening period. Patients received treatment weekly for up to 12 weeks. The primary endpoint measures complete wound closure by 12 weeks as determined by the investigator and are confirmed using an independent, blinded Wound Core Lab. Secondary endpoints include complete wound closure rates for those patients that complete all scheduled treatments, time to wound closure, number of applications, proportion of patients achieving at least a 50% reduction in wound size by day 28 and number of re-occurrences. Patients randomized to the control group who did not heal within 12 weeks entered a cross-over arm for evaluation in an additional 12 week open-label treatment with Grafix.

[Leirum]

Was an excellent trade but even more Money could be made trough New Venture Tech AG - as well controlled by Friedli - who controls Osiris. In April 2012, the stock was CHF 1.30 now CHF 7.-- The leverage was higher than by owing directly Osir. I took the Chips of the table.

Now when you ask the next one. Look at DECN - being in fight with J&J due to patent litigation but the way it Looks, the Courts are turning against J&J. Always open for a second opinion however placed some of my Chips here.

[RickKayne]

Good trade.
What's the next one?

[surf1944]

Time to take OSIR off the table for now, sold out....

[ECole]

Important Business updates during Conference call- Read the details of the efficacy and safety of Grafix in the treatment of chronic diabetic foot ulcers

http://www.earningsimpact.com/Transcript/82831/OSIR/Business-Update-Call

[surf1944]

8:06AM Osiris Therapeutics: Grafix demonstrates overwhelming efficacy in landmark stem cell study for the treatment of diabetic foot ulcers; Grafix closes three times as many wounds as standard of care (OSIR) 10.66 : Co announced hat it has entered into a definitive agreement to sell Ultratroc Gmbh, a manufacturer of compressed air dryers located in Flensburg, Germany, to IJW Anlagenbau Gmbh (IJW). The sale of the Flensburg manufacturing facility will be effective 23 September. Jan Weiner, the Plant Manager of Ultratroc Gmbh until 2010, is a co-owner of IJW and returns as Manager of the Flensburg facility and its 38 employees. He brings many years of experience in the dryer business and will help ensure a smooth transition for Ultratroc's current Customers, suppliers, employees, and the local Flensburg community. The trial also reached statistical significance in favor of Grafix on all top-line secondary endpoints, demonstrating faster wound closure and a reduction in the number of treatments needed to achieve wound closure.

[LasNubes]

I was in here last summer and took a beating, but I have it on my watch list again for this coming week.

[surf1944]

http://investor.osiris.com/

[wesley_]

back up we go

[MinnieM]

Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

http://ih.advfn.com/p.php?pid=nmona&article=56592475

[surf1944]

7:07AM Osiris Therapeutics receives title of european orphan drug designation for Prochymal (OSIR) 7.02 : Co announced today that the European Medicines Agency has designated Osiris as the Orphan Drug title holder for Prochymal. The EU Commission adopted the decision to transfer the designation of Prochymal (ex-vivo cultured adult human mesenchymal stem cells) as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council. The Decision will appear in the EU Community Register of Orphan Medicinal Products.

[umiak]

hey karin, all in clsn 14 calls. good to here from you, hope life is treating you well. what a year it has been.

[MinnieM]

Haven't been here in awhile... figured I'd better check it out. ;)

[surf1944]

1:27AM Osiris Therapeutics regains worldwide rights to Prochymal and Chondrogen from Sanofi (SNY) unit Genzyme (OSIR) 10.24 : Co announces the conclusion of its collaboration with Genzyme, a Sanofi (SNY) co. As the Collaboration Agreement is now ended, all rights to Prochymal and Chondrogen worldwide revert back to Osiris. Co is now free to commercialize or enter into commercialization agreements for Prochymal and Chondrogen with other parties without limitation. Both parties have agreed to an orderly conclusion of the collaboration, with no further financial responsibilities for either party, and an amicable end to their relationship.

[surf1944]

The short ratio is also helping to push the share price higher:

Avg Vol (3 month)3: 444,939
Avg Vol (10 day)3: 116,300
Shares Outstanding5: 32.87M
Float: 15.23M
% Held by Insiders1: 53.64%
% Held by Institutions1: 14.20%
Shares Short (as of Aug 15, 2012)3: 3.93M
Short Ratio (as of Aug 15, 2012)3: 15.30
Short % of Float (as of Aug 15, 2012)3: 27.80%
Shares Short (prior month)3: 3.99M

[surf1944]

OSIR may be testing the $14 area in the coming weeks, but take stock off the table in stages, using time, price, profit % & future price gauges....

[Apophis]

my shares are doubled but when do we exit this stock?

[turbodog]

OSIR VS SANOFI

http://www.scimitarequity.com/blog/2012/07/31/osiris-osir-vm-randal-called-let-my-therapy-go-and-keep-the-shares/

[surf1944]

8:05AM Osiris Therapeutics beats by $0.02 (OSIR) 10.03 : Reports Q2 (Jun) ($0.13), $0.02 better than the Capital IQ Consensus Estimate of ($0.15); revenues rose year/year to $1.6 mln (up from $130K) vs the $1.57 mln consensus.